Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019;380:2225-2236.,Fischer K, Al-Sawaf O, Bahlo J, et al. Fixed-duration venetoclax plus obinutuzumab improves progression-free survival and minimal residual disease negativity in patients with previously untreated CLL and comorbidities. 24th Congress of EHA, abstract S149.
Grote verschillen tussen landen in toegang tot nieuwe medicatie
mrt 2024 | Borstkanker, Dermato-oncologie, Gynaecologische oncologie, Leukemie, Longoncologie, Uro-oncologie